Description

Mirapex (pramipexol) tablets 1 mg. №30

Ingredients

Active ingredient: Pramipexole 1 mg

Dosage

Dosage: The usual starting dose of Mirapex is 0.125 mg taken once daily 2-3 hours before bedtime. The dose may be gradually increased every 5-7 days.

Indications

Indications: Mirapex is indicated for the treatment of Parkinson’s disease and Restless Legs Syndrome (RLS).

Contraindications

Contraindications: Mirapex is contraindicated in patients with a known hypersensitivity to pramipexole or any of the inactive ingredients in the formulation.

Directions

Directions: Swallow the tablets whole with a glass of water. Do not crush, chew, or break the tablets.

Scientific Evidence

Mirapex (pramipexole) has been extensively studied for its efficacy in the treatment of Parkinson’s disease and Restless Legs Syndrome. Research studies have demonstrated that pramipexole, the active ingredient in Mirapex, acts as a dopamine agonist, stimulating dopamine receptors in the brain. This action helps improve motor symptoms in Parkinson’s disease and alleviates symptoms of Restless Legs Syndrome.

Additional Information

Mirapex is generally well-tolerated, but common side effects may include nausea, dizziness, and drowsiness. It is important to follow the prescribed dosage and consult with a healthcare provider before starting Mirapex therapy.

Pharmacological Effects

Pramipexole, the active ingredient in Mirapex, exerts its pharmacological effects by acting as a selective dopamine agonist. By stimulating dopamine receptors in the brain, pramipexole helps to restore dopamine levels, which are crucial for controlling movement and coordination. This mechanism of action makes Mirapex an effective treatment for Parkinson’s disease and Restless Legs Syndrome.

Clinical Trials and Comparative Effectiveness

Clinical trials have shown that Mirapex is effective in improving motor symptoms in patients with Parkinson’s disease and reducing the symptoms of Restless Legs Syndrome. In comparative studies, Mirapex has demonstrated similar or superior efficacy compared to other dopamine agonists. The favorable efficacy profile and tolerability make Mirapex a preferred choice in the management of these conditions.

References:
1. Oertel WH, et al. Pramipexole in the treatment of Parkinson’s disease. Drugs. 2003;63(17):1877-93.
2. Trenkwalder C, et al. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov Disord. 2008;23(13):207-13.